Mantle Cell Lymphoma
News
Ibrutinib bodes well for relapsed mantle-cell lymphoma
Key clinical point: Ibrutinib significantly improved progression-free survival, compared with temsirolimus in patients with relapsed or refractory...
News
Ki-67 bests cytology, growth pattern as prognostic factor for MCL
Key clinical point: The Ki-67 index was superior to cytology and growth pattern as a prognostic factor in mantle-cell lymphoma (MCL).
News
Lenalidomide plus rituximab achieves 87% response rate
Key clinical point: First-line combination biologic therapy with lenalidomide plus rituximab produced an 87% overall response rate in stage 3 or 4...
Conference Coverage
RBAC500 safe, effective for elderly patients with mantle cell lymphoma
Key clinical point: Reducing the dose of cytarabine from 800 mg/m2 to 500 mg/m2 allowed a regimen of rituximab, bendamustine, and cytarabine to be...
News
Bendamustine regimen may be induction-therapy option in mantle cell lymphoma
Key clinical point: Rituximab plus bendamustine may prove to be an option for induction therapy prior to autologous stem cell transplant in...
Conference Coverage
Swapping bortezomib for vincristine improves PFS in mantle cell lymphoma
Key clinical point: Substituting bortezomib for vincristine may bring clinical benefit to patients with newly diagnosed mantle cell lymphoma who...
Commentary
Drugs approved in 2013
Conference Coverage
ONO-4059 makes waves in heavily pretreated CLL
Major finding: The response rate was 89% overall and 71% for patients with 17p deletion. Data source: A prospective, phase I dose-escalation study...
News
Ibrutinib approved for mantle cell lymphoma
News
FDA approves lenalidomide for mantle cell lymphoma
Conference Coverage
'Highest response rate ever reported' in relapsed mantle cell lymphoma
Major Finding: In an efficacy cohort of 110 patients with relapsed or refractory mantle cell lymphoma, 22% had a complete response and 46% a...